A study to elucidate the clinical factors of contrast-enhanced MRI in prostate cancer clinical practice

A study to elucidate the clinical factors of contrast-enhanced MRI in prostate cancer clinical practice - Is contrast-enhanced MRI necessary for prostate cancer?

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046470

Enrollment

400

Registered

2021-12-24

Start date

2021-11-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients who performed mpMRI (T2WI, DWI, DCE-MRI) due to elevated PSA levels. 2. MRI-US fusion biopsy proven prostate cancer(PI-RADS version 2.1 category 3 or more or likert scale category 3 or more)

Exclusion criteria

Exclusion criteria: 1. Patients who lack of imaging quality Investigator judged ineligible as a subject 2. Unevaluable of PI-RADS category due to lack of T2WI or DWI or DCE-MRI

Design outcomes

Primary

Measure	Time frame
To evaluate the correlation between clinicopathological and contrast enhancement, treatment evaluation, prediction of treatment effect and predicting prognosis after treatment by dynamic contrast-enhanced MRI.	—

Secondary

Measure	Time frame
To evaluate the impact of dynamic contrast-enhanced MRI on practical clinical reading.	—

Countries

Japan

Contacts

Public ContactTsutomu Tamada

Kawasaki Medical School Department of Radiology

ttamada@med.kawasaki-m.ac.jp+81-86-462-1111

Outcome results